Orexo: Zubsolv Rx Data week 3, 2017

According to latest Symphony Health Solutions Rx data, Zubsolv tablets showed a market share of 5.58% (5.64%), 4-week rolling average. The total number of Zubsolv tablets sold week 3 (2) reaching 318,698 (329,152). Zubsolv prescriptions (TRx) recorded a market share of 5.56% (5.59%), 4-week rolling average. Total number of prescriptions reaching 11,565 (11,617) during the week.

The overall market (buprenorphine/naloxone) showed a y/y growth rate of 6.8% (8.9%) (4-week rolling average unit sales). TRx showed a y/y growth rate by 7.1% (8.2%) (4-week rolling average).

Författaren ägde vid analystillfället aktier i bolaget.

Fler bolagsanalyser

Här listas fler bolagsanalyser ifrån Redeyes analysavdelning.

Publicerad Rubrik Analystyp
2017-03-22 Analys
2017-03-21 Update
2017-03-21 Update
2017-03-17 Update
2017-03-16 Update
2017-03-14 Update
2017-03-14 Update
2017-03-10 Update
2017-03-10 Update
2017-03-07 Update
2017-03-07 Update
2017-03-07 Update
2017-03-07 Update
2017-03-06 Update
2017-03-06 Update
2017-03-03 Update
2017-03-03 Update
2017-03-03 Update
2017-03-03 Update
2017-03-01 Update
2017-02-28 Update
2017-02-27 Update
2017-02-27 Update
2017-02-27 Update
2017-02-27 Update